IP Library Granted Patent US 7,053,242
Granted Patent B1
US 7,053,242 · App. 10/089,036 · Granted May 30, 2006

Carbon monoxide source for preparation of transition-metal-carbonyl-complexes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,053,242
App. No.
10/089,036
Granted
May 30, 2006
Kind
B1
Abstract

The present invention relates to compounds that have a novel use as a carbon monoxide source and optionally as a reducing agent in the preparation of transition metal carbonyl complexes. The compounds are in general compounds of formula (I) wherein X 1 , X 2 and X 3 are the same or different and either a Lewis base or hydride and Y is a sigma donating group. The invention furthermore relates to a method for the preparation of borane carbonate and to the use of H 3 BCO as a reducing agent.

Claims (56)

1. A method of using a compound, the method comprising:

preparing a transition metal carbonyl complex using a compound of the following formula as a CO source and as a reducing agent, wherein the using comprises:

releasing CO from the compound; and

reducing a metal, with which the transition metal carbonyl complex is to be formed, with a hydride substituent attached to boron (B),

wherein:

X 4 is —H;

X 5 and X 6 are substituents which are independently selected from the group consisting of —H, —NH x R y and R, wherein x and y are integers and x+y=3, wherein R is bound by a carbon atom to the nitrogen or boron, respectively;

Z is —OH, —OH 2 , —OR or —NHR, wherein R is a substituent that comprises a carbon atom and is bound by the carbon atom to the nitrogen or oxygen, respectively;

A is a cation selected from hydrogen and an alkali or alkaline earth metal;

n is 0, −1 or −2; and

a and m are independently 0, +1 or +2.

2. The method as claimed in claim 1 , wherein the transition metal in the transition metal carbonyl complex is selected from the groups V-B to VIII-B metals.

3. The method as claimed in claim 2 , wherein the transition metal in the transition metal carbonyl complex is selected from the group consisting of Vanadium (V), Chromium (Cr), Molybdenum (Mo), Tungsten (W), Manganese (Mn), Technetium (Tc), Rhenium (Re), Iron (Fe), Ruthenium, (Ru), Osmium (Os), Cobalt (Co), Rhodium (Rh), Iridium (Ir) and Nickel (Ni).

4. A method for preparation of boranocarbonate, comprising:

a) reacting BH 3 -THF or an adduct thereof in THF or a mixture of THF and an organic aprotic solvent with CO to generate H 3 BCO;

b) passing the H 3 BCO thus generated through a cold solution of a hydroxide with a mono or dicationic counter ion and a lower alkyl C 1-5 alcohol; and

c) after a suitable reaction time, heating the alcoholic solution to precipitate the boranocarbonate.

5. The method of claim 4 , wherein the adduct is H 3 B(Et 2 O).

6. The method of claim 4 , wherein the hydroxide is selected from the group consisting of potassium hydroxide, sodium hydroxide and tetraalkyl ammonium hydroxide.

7. The method of claim 4 , wherein the alcohol is selected from the group consisting of methanol, ethanol and isopropanol.

8. The method of claim 1 , further comprising making a solution comprising the compound and a protic solvent.

9. The method of claim 8 , further comprising heating the solution, wherein the heating of the solution comprises releasing carbon monoxide.

10. The method of claim 1 , further comprising making a solution comprising the compound and a Lewis acid.

11. The method of claim 10 , further comprising heating the solution, wherein the heating of the solution comprises releasing carbon monoxide.

12. The method of claim 1 , further comprising making a solution comprising the compound and water.

13. The method of claim 12 , further comprising heating the solution, wherein the heating of the solution comprises releasing carbon monoxide.

14. The method of claim 1 , wherein n is −1 or −2, m is +1 or +2, and m+n is equal to zero.

15. The method of claim 1 , wherein (a×m)+n is equal to zero.

16. The method of claim 1 , wherein at least one of X 5 and X 6 is —H.

17. A method of using a compound, the method comprising:

preparing a transition metal carbonyl complex using a compound of the following formula as a CO source and as a reducing agent, wherein the using comprises:

releasing CO from the compound; and

reducing a metal, with which the transition metal carbonyl complex is to be formed, with a hydride substituent attached to boron (B),

wherein:

X 1 , X 2 and X 3 are the same or different and are selected from the group consisting of Lewis bases and hydrides;

Y is a sigma donating group;

A is a cation selected from the group consisting of hydrogen, alkali and alkaline earth metals;

n is 0, −1 or −2;

m is 0, +1 or +2; and

a is 0, +1 or +2.

18. The method of claim 17 , further comprising mixing the compound with a protic solvent or a Lewis acid.

19. The method of claim 17 , further comprising making an aqueous solution comprising the compound.

20. The method of claim 17 , wherein: (a×m)+n is equal to zero.

21. The method of claim 19 , wherein the compound is:

a borane carbonate compound in which X 1 , X 2 and X 3 are —H, and Y is —OH 2 ;

a corresponding salts of the mono- or dideprotonated borane carbonate [H 3 BCO 2 ] 2− ;

a borane amino acid in which X 1 is NH 3 , X 2 and X 3 are —H, and Y is —OH; or

a corresponding salt of the monodeprotonated ammine borane carbonate [(NH 3 )H 2 BCO 2 ] − .

22. The method of claim 19 , wherein the compound is an alkylated borane amino acid in which X 1 is —NH x R y with x+y=3, wherein R is alkyl or aryl and is bound by a carbon atom to the nitrogen, X 2 and X 3 are —H, and Y is —OH.

23. The method of claim 19 , wherein X 1 is an organic substituent bound by a carbon atom to boron, X 2 and X 3 are —H, and Y is —OH 2 .

24. The method of claim 19 , wherein the compound is selected from the group consisting of:

boranocarbonate derivatives selected from the group consisting of [H 3 B—COOH 2 ], [H 3 B—COOH]M, [H 3 B—COO]M 2 and Na[H 3 B—COOCH 3 ], wherein M is an alkali cation;

boranocarbonates selected from the group consisting of Na[H 3 BCONHCH 3 ] and M[H 3 B—CONH 2 ], wherein M is an alkali cation;

ammine-boranocarbonates selected from the group consisting of [H 3 N—BH 2 —COOH], [H 3 N—BH 2 —COO]Li, [(CH 3 ) 3 N—BH 2 —COOH], [(CH 3 )H 2 N—BH 2 —COOH], [(CH 3 )H 2 N—BH 2 —COO]Li and [(CH 3 )H 2 N—BH 2 —COOCH 3 ]; and

amine-boranocarbamates selected from the group consisting of [H 3 N—BH 2 —CONH 2 ] and [(CH 3 ) 2 HN—BH 2 —CONHC 2 H 5 ].

25. The method of claim 1 , wherein R is alkyl or aryl.

Assignments (1)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →